Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Therapeutically Promising PNA Complementary to a Regulatory Sequence for c-myc: Pharmacokinetics in an Animal Model of Human Burkitt's Lymphoma
Ist Teil von
Oligonucleotides, 2005-01, Vol.15 (2), p.85-93
Ort / Verlag
United States: Mary Ann Liebert, Inc
Erscheinungsjahr
2005
Quelle
MEDLINE
Beschreibungen/Notizen
In Burkitt's lymphoma (BL) cells c-
myc
is often translocated in proximity to the Eµ enhancer of the
Ig gene locus. This translocation causes c-
myc
hyperexpression and an increase in the cells' proliferative
capacity. A peptide nucleic acid (PNA) complementary to enhancer Eµ intronic sequence
(PNAEµ), linked to a nuclear localization signal (NLS), selectively and specifically blocks the expression
of the c-
myc
oncogene under Eµ control
in vitro
, suggesting potential therapeutic use. To explore
this issue further, we have determined the pharmacokinetics of
14
C-labeled PNAEµ in SCID mice
where a human tumor is established by inoculation of cells from a BL cell line. The data demonstrate
that the compound has a relatively long life
in vivo
in tissues and, in particular, in BL tumor mass.
Furthermore, in this animal model, PNAEµ shows low or no toxicity. All these results are in favor of
a successful preclinical application in a BL human tumor animal model of a PNA targeting a regulatory,
nontranscribed DNA sequence that can selectively inhibit the hyperexpression of a translocated
gene linked to neoplastic cell expansion.